FDA moves to revoke approval of Avastin for treatment of breast cancer

Avastin, the world's best-selling cancer drug, doesn't prolong the life of breast cancer patients, the FDA says, but the announcement does not affect the use of Avastin against other types of cancer. Some Avastin proponents call for its continued use by breast cancer patients.The Food and Drug Administration on Thursday moved toward revoking approval of the blockbuster cancer drug Avastin as a treatment for breast cancer, drawing criticism for limiting treatment options for desperately ill women.

Read the whole article on LA Times - Health

More from LA Times - Health